Longevity & AgingFirst TRPML1 Drug Enters Human Trials Targeting Brain's Cellular Cleanup System
A Cambridge biotech called Lysoway Therapeutics has dosed the first human participant in a Phase I trial of LW-1017, a drug designed to fight Alzheimer's and Parkinson's by restoring the brain's cellular waste-disposal system. Unlike most Alzheimer's drugs that target amyloid or tau proteins after they've built up, LW-1017 activates a channel called TRPML1 that helps lysosomes — the cell's recycling units — function more efficiently. As we age, this cleanup system slows down, allowing damaged proteins to accumulate and neurons to become stressed. This trial, conducted in healthy volunteers in Melbourne, is the first time a TRPML1 activator has entered clinical testing in humans. It's an early safety trial, so effectiveness in patients hasn't been tested yet, but it represents a meaningful upstream shift in how researchers are approaching brain aging.
